Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Multiple Sclerosis

Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients

Ann Neurol.

Dalla Costa G, Martinelli V, Moiola L, Sangalli F, Colombo B, Finardi A, Cinque P, Kolb EM, Haghikia A, Gold R, Furlan R, Comi G

doi: 10.1002/ana.25437.

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

Multiple Sclerosis

Natalizumab-associated progressive multifocal leukoencephalopathy in Germany

Neurology.

Blankenbach K, Schwab N, Hofner B, Adams O, Keller-Stanislawski B, Warnke C

doi: 10.1212/WNL.

Multiple Sclerosis

Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients

J Neurol Sci.

Heesen C, Kleiter I, Meuth SG, Krämer J, Kasper J, Köpke S, Gaissmaier W

doi: 10.1016/j.jns.2017.03.001.

SPECIAL REPORT

Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis

Ther Adv Neurol Disord.

Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S

doi: 10.1177/

Multiple Sclerosis

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis

JAMA Neurol.

Naegelin Y, Naegelin P, von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ, Scotti B, Zecca C, Gobbi C, Kappos L, Derfuss T

doi: 10.1001/jamaneurol.

Multiple Sclerosis

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis

JAMA Neurol.

Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand'Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Slee M, Shaygannejad V, Boz C, Lechner-Scott J, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambiatos A, Van der Walt A, Butzkueven H, Kalincik T, MSBase Study Group

doi: 10.1001/jamaneurol.

Multiple Sclerosis

Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study

Lancet Neurol.

Filippi M, Preziosa P, Meani A, Ciccarelli O, Mesaros S, Rovira A, Frederiksen J, Enzinger C, Barkhof F, Gasperini C, Brownlee W, Drulovic J, Montalban X, Cramer SP, Pichler A, Hagens M, Ruggieri S, Martinelli V, Miszkiel K, Tintorè M, Comi G, Dekker I, Uitdehaag B, Dujmovic-Basuroski I, Rocca MA

doi: 10.1016/

Related content

Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients

Vaccination Readiness in Multiple Sclerosis

Natalizumab-associated progressive multifocal leukoencephalopathy in Germany

Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis

Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study